Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nuvigil Jet Lag Indication Could Triple Potential Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

Cephalon's sNDA, if approved, will create the marketing challenge of reaching a population of acute, not chronic, suffers.

You may also be interested in...



FDA Pushes Back Action Date For Nuvigil Label Expansion Due To New Data

Cephalon, which has positioned Nuvigil to replace Provigil as the latter sleep drugs faces patent expiry, hopes to add treatment of jet lag to label.

FDA Pushes Back Action Date For Nuvigil Label Expansion Due To New Data

Cephalon, which has positioned Nuvigil to replace Provigil as the latter sleep drugs faces patent expiry, hopes to add treatment of jet lag to label.

An Easy Landing? Cephalon Scores Priority Review For Nuvigil In Jet Lag Disorder

Some, however, remain skeptical of the medicine's potential after the Provigil patent expires.

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel